February 3, 2014 / 12:21 PM / 4 years ago

Pfizer breast cancer drug succeeds in mid-stage trial

Feb 3 (Reuters) - Pfizer Inc said its experimental breast cancer drug, in a mid-stage trial, showed a statistically significant improvement in patients' survival rates without their disease worsening.

The drug palbociclib was tested in post-menopausal patients in combination with the hormonal therapy letrozole, and results were compared with patients receiving only letrozole.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below